Edition:
India

Cocrystal Pharma Inc (COCP.OQ)

COCP.OQ on NASDAQ Stock Exchange Capital Market

0.46USD
2:29am IST
Change (% chg)

$-0.15 (-25.04%)
Prev Close
$0.62
Open
$0.62
Day's High
$0.62
Day's Low
$0.45
Volume
86,367
Avg. Vol
12,431
52-wk High
$5.27
52-wk Low
$0.45

Latest Key Developments (Source: Significant Developments)

Cocrystal Pharma Reports Qtrly Loss Per Share $0.06
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.COCRYSTAL PHARMA INC - QTRLY LOSS PER SHARE $0.06.COCRYSTAL PHARMA INC - AS OF SEPTEMBER 30, 2019, COMPANY HAD ABOUT $6 MILLION CASH ON HAND.COCRYSTAL PHARMA INC - EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS THROUGH END OF 2020.  Full Article

Cocrystal Pharma Presents Positive Data From U.S. Phase 2a Study Of CC-31244 Demonstrating Ability To Identify Patients More Likely To Respond To Ultrashort Treatment Of HCV
Monday, 11 Nov 2019 

Nov 11 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA PRESENTS POSITIVE DATA FROM U.S. PHASE 2A STUDY OF CC-31244 DEMONSTRATING ABILITY TO IDENTIFY PATIENTS MORE LIKELY TO RESPOND TO ULTRASHORT TREATMENT OF HCV.COCRYSTAL PHARMA INC - RESULTS FROM PHASE 2A STUDY DEMONSTRATED THAT EIGHT OF 12 PATIENTS ACHIEVED PRIMARY ENDPOINT OF SUSTAINED VIROLOGIC RESPONSE 12.COCRYSTAL PHARMA INC - FREQUENCY OF NAÏVE CD8+ T CELLS WAS LOWER WHILE FREQUENCY OF EFFECTOR MEMORY CD8+ T CELLS WAS HIGHER IN SVR PATIENTS.COCRYSTAL PHARMA INC - DIFFERENCES BETWEEN FREQUENCY OF NAÏVE CD8+ T CELLS AND FREQUENCY OF EFFECTOR MEMORY CD8+ T CELLS NOT STATISTICALLY SIGNIFICANT.  Full Article

Cocrystal Pharma Expects To Grant Underwriters Option To Purchase Up To Additional 15% Common Shares
Thursday, 31 Oct 2019 

Oct 30 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.COCRYSTAL PHARMA - EXPECTS TO GRANT UNDERWRITERS 45-DAY OPTION TO PURCHASE UP TO ADDITIONAL 15% OF SHARES OF COMMON STOCK OFFERED IN PUBLIC OFFERING.  Full Article

Cocrystal Pharma Q2 Revenue $592,000
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $592,000.AS OF JUNE 30, 2019, COCRYSTAL HAD APPROXIMATELY $7.5 MILLION CASH ON HAND.CO EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS THROUGH Q1 OF 2020.EXPECTS TO INITIATE PHASE 1 STUDY EVALUATING CC-42344 FOR TREATMENT OF INFLUENZA IN Q4 2020.  Full Article

Cocrystal Pharma Files For Resale Of Up To 1.7 Million Shares Of Common Stock
Thursday, 25 Apr 2019 

April 25 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA INC FILES FOR RESALE OF UP TO 1.7 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Cocrystal Pharma Announces Collaboration Agreement With Merck
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH MERCK.COCRYSTAL PHARMA INC - COCRYSTAL WILL BE PAID AN UNDISCLOSED UPFRONT SUM.COCRYSTAL PHARMA INC - MERCK TO FUND RESEARCH AND DEVELOPMENT FOR PROGRAM.COCRYSTAL PHARMA INC - MERCK WILL BE RESPONSIBLE FOR WORLDWIDE COMMERCIALIZATION OF ANY PRODUCTS DERIVED FROM COLLABORATION.COCRYSTAL PHARMA - ELIGIBLE TO RECEIVE PAYMENTS RELATED TO DESIGNATED DEVELOPMENT, REGULATORY & SALES MILESTONES WITH POTENTIAL TO EARN UP TO $156 MILLION.  Full Article

Cocrystal Pharma Qtrly Loss Per Share $0.06
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Cocrystal Pharma Inc ::QTRLY LOSS PER SHARE $0.06 .  Full Article

Cocrystal Pharma Inc Reports Qtrly Net Loss Of $1.3 Mln Vs $1 Mln
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.COCRYSTAL PHARMA INC - QTRLY NET LOSS $1.3 MILLION VERSUS $1 MILLION.  Full Article

Cocrystal Pharma Provides Corporate Overview
Thursday, 22 Mar 2018 

March 22 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE OVERVIEW AND BUSINESS OUTLOOK.COCRYSTAL PHARMA - ‍AS OF DEC 31, 2017, CO HAD $2.1 MILLION CASH; BASED ON CURRENT PROJECTIONS, CO BELIEVES IT HAS SUFFICIENT FUNDS THROUGH Q2 OF 2018​.  Full Article

Cocrystal Pharma Announces Uplist To The Nasdaq Capital Market
Monday, 12 Mar 2018 

March 12 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA ANNOUNCES UPLIST TO THE NASDAQ CAPITAL MARKET.COCRYSTAL PHARMA INC - COMMON STOCK WILL COMMENCE TRADING ON NASDAQ CAPITAL MARKET ON, MARCH 12, 2018​.  Full Article